View ValuationSelvita 향후 성장Future 기준 점검 4/6Selvita (는) 각각 연간 43.3% 및 8.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 74.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7% 로 예상됩니다.핵심 정보43.3%이익 성장률74.63%EPS 성장률Life Sciences 이익 성장20.4%매출 성장률8.9%향후 자기자본이익률7.01%애널리스트 커버리지Low마지막 업데이트30 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.공고 • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025공고 • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025공고 • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • May 23First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023)First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공고 • May 08Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o.Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day. Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024.Reported Earnings • Mar 31Full year 2023 earnings released: EPS: zł3.80 (vs zł1.65 in FY 2022)Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공고 • Mar 19Selvita S.A. Launches Biologic Drug Discovery and Development ServicesSelvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market.공고 • Jan 19+ 3 more updatesSelvita S.A. to Report First Half, 2024 Results on Sep 25, 2024Selvita S.A. announced that they will report first half, 2024 results on Sep 25, 2024Reported Earnings • Jun 04First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.공고 • Jun 02Selvita S.A., Annual General Meeting, Jun 27, 2023Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time.공고 • Jan 31+ 3 more updatesSelvita S.A. to Report Q3, 2023 Results on Nov 15, 2023Selvita S.A. announced that they will report Q3, 2023 results on Nov 15, 2023공고 • Nov 23Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million.Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: PLN 78.7Reported Earnings • Sep 17Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.공고 • Jun 07Selvita S.A., Annual General Meeting, Jun 30, 2022Selvita S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Germany.Buying Opportunity • May 03Now 23% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €20.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.Buying Opportunity • Apr 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €20.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.Reported Earnings • Apr 05Full year 2021 earnings released: EPS: zł0.81 (vs zł1.05 in FY 2020)Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany.Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be zł20.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years.공고 • Feb 02Selvita Announces Management ChangesSelvita informed about signing a preliminary contract to purchase another plot of land to expand its own laboratory space and secure further organic growth in Krakow, Poland. The integrated departments providing drug discovery services, operating in Krakow, Poznan, and Zagreb, will be led by Dr. Adrijana Vinter, who takes on a role of the Global Head of Drug Discovery and joins Selvita Management Board. Prior to that, for the past four years, Dr. Vinter has held the position of Managing Director at Fidelta. The Company intends to also integrate its business development and sales activities. Dr. Milosz Gruca, who will assume the position of Chief Commercial Officer, Executive Vice President, will be managing teams responsible for the development and sales of the integrated Selvita and Fidelta services offer in the area of drug discovery and development. Growing Group's scale of operations and its further development plans have led to creation of the Chief Operating Officer function, assumed by Dr. Miroslawa Zydron, the current Chemistry Department Director. Dr. Zydron will be responsible for the Group's operational activities, investments, and infrastructure management.Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues exceed analyst expectationsThird quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Germany.Reported Earnings • Sep 23Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020).Reported Earnings • May 30First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue.이익 및 매출 성장 예측DB:787 - 애널리스트 향후 추정치 및 과거 재무 데이터 (PLN Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028437313683412/31/2027402213372512/31/202636412266753/31/2026359-46372N/A12/31/202537116673N/A9/30/2025374-36270N/A6/30/202537405768N/A3/31/2025360-54656N/A12/31/2024346-64564N/A9/30/2024334541765N/A6/30/2024329473177N/A3/31/2024337653496N/A12/31/202335270579N/A9/30/202335820-2065N/A6/30/202336931-3272N/A3/31/202337224-5056N/A12/31/202236526-2575N/A9/30/2022364202499N/A6/30/2022351112885N/A3/31/2022329125696N/A12/31/2021316156085N/A9/30/2021260125364N/A6/30/2021216182946N/A3/31/2021181221633N/A12/31/2020142181429N/A9/30/202015821622N/A6/30/20209915N/AN/AN/A3/31/20206391212N/A12/31/2019547N/A6N/A9/30/2019222N/AN/AN/A3/31/20198110N/A6N/A12/31/20187710N/A12N/A12/31/2017564N/A11N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 787 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.1%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 787 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 787 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 787 의 수익(연간 8.9%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 787 의 수익(연간 8.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 787의 자본 수익률은 3년 후 7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/19 03:46종가2026/08/19 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Selvita S.A.는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Beata Szparaga-WasniewskaBiuro maklerskie mBankuSylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.Tomasz SokolowskiErste Bank Polska S.A.4명의 분석가 더 보기
공고 • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.
Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
공고 • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025
공고 • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025
공고 • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.
Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • May 23First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023)First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공고 • May 08Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o.Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day. Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024.
Reported Earnings • Mar 31Full year 2023 earnings released: EPS: zł3.80 (vs zł1.65 in FY 2022)Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공고 • Mar 19Selvita S.A. Launches Biologic Drug Discovery and Development ServicesSelvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market.
공고 • Jan 19+ 3 more updatesSelvita S.A. to Report First Half, 2024 Results on Sep 25, 2024Selvita S.A. announced that they will report first half, 2024 results on Sep 25, 2024
Reported Earnings • Jun 04First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
공고 • Jun 02Selvita S.A., Annual General Meeting, Jun 27, 2023Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time.
공고 • Jan 31+ 3 more updatesSelvita S.A. to Report Q3, 2023 Results on Nov 15, 2023Selvita S.A. announced that they will report Q3, 2023 results on Nov 15, 2023
공고 • Nov 23Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million.Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: PLN 78.7
Reported Earnings • Sep 17Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
공고 • Jun 07Selvita S.A., Annual General Meeting, Jun 30, 2022Selvita S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Germany.
Buying Opportunity • May 03Now 23% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €20.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.
Buying Opportunity • Apr 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €20.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.
Reported Earnings • Apr 05Full year 2021 earnings released: EPS: zł0.81 (vs zł1.05 in FY 2020)Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany.
Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be zł20.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years.
공고 • Feb 02Selvita Announces Management ChangesSelvita informed about signing a preliminary contract to purchase another plot of land to expand its own laboratory space and secure further organic growth in Krakow, Poland. The integrated departments providing drug discovery services, operating in Krakow, Poznan, and Zagreb, will be led by Dr. Adrijana Vinter, who takes on a role of the Global Head of Drug Discovery and joins Selvita Management Board. Prior to that, for the past four years, Dr. Vinter has held the position of Managing Director at Fidelta. The Company intends to also integrate its business development and sales activities. Dr. Milosz Gruca, who will assume the position of Chief Commercial Officer, Executive Vice President, will be managing teams responsible for the development and sales of the integrated Selvita and Fidelta services offer in the area of drug discovery and development. Growing Group's scale of operations and its further development plans have led to creation of the Chief Operating Officer function, assumed by Dr. Miroslawa Zydron, the current Chemistry Department Director. Dr. Zydron will be responsible for the Group's operational activities, investments, and infrastructure management.
Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues exceed analyst expectationsThird quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Germany.
Reported Earnings • Sep 23Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020).
Reported Earnings • May 30First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue.